Calidi Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Calidi Biotherapeutics
CLDI Stock   1.24  0.05  3.88%   
Calidi Biotherapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Calidi Biotherapeutics' valuation are provided below:
Gross Profit
31 K
Market Capitalization
8.9 M
Enterprise Value Revenue
49.4238
Earnings Share
0.36
We have found one hundred twenty available fundamental signals for Calidi Biotherapeutics, which can be analyzed and compared to other ratios and to its rivals. Traders should compare all of Calidi Biotherapeutics prevailing fundamentals against the fundamentals between 2010 and 2025 to make sure the company is sustainable this year. The current Market Cap is estimated to decrease to about 26.5 M. Enterprise Value is estimated to decrease to about 32.1 M
Check Calidi Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Calidi Biotherapeutics' main balance sheet or income statement drivers, such as Tax Provision of 13.6 K, Depreciation And Amortization of 1.6 M or Interest Expense of 1.2 M, as well as many indicators such as Price To Sales Ratio of 1 K, Dividend Yield of 0.14 or PTB Ratio of 6.28. Calidi financial statements analysis is a perfect complement when working with Calidi Biotherapeutics Valuation or Volatility modules.
  
Build AI portfolio with Calidi Stock
Check out the analysis of Calidi Biotherapeutics Correlation against competitors.
For more detail on how to invest in Calidi Stock please use our How to Invest in Calidi Biotherapeutics guide.

Calidi Biotherapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets14.9 M14.2 M4.1 M
Slightly volatile
Short and Long Term Debt Total5.9 M7 M10 M
Slightly volatile
Other Current Liabilities2.8 M3 M6.1 M
Slightly volatile
Total Current Liabilities15.6 M9.5 M12.6 M
Slightly volatile
Property Plant And Equipment Net2.3 M2.9 M1.3 M
Slightly volatile
Accounts Payable1.9 M2.1 M1.2 M
Slightly volatile
Cash10.1 M9.6 M1.8 M
Slightly volatile
Non Current Assets Total3 M4 M1.9 M
Slightly volatile
Non Currrent Assets Other537.2 K892 K571.2 K
Pretty Stable
Other Assets491.7 K833.8 K597 K
Very volatile
Long Term Debt570 K600 K4.8 M
Slightly volatile
Cash And Short Term Investments10.1 M9.6 M1.8 M
Slightly volatile
Common Stock Shares Outstanding655 K664.4 K2.2 M
Slightly volatile
Liabilities And Stockholders Equity14.9 M14.2 M4.1 M
Slightly volatile
Non Current Liabilities Total2.6 M2.7 M12.1 M
Slightly volatile
Capital Lease Obligations1.9 M3.3 M924.4 K
Slightly volatile
Other Current Assets580.8 K636 K259.4 K
Slightly volatile
Other Stockholder Equity129.4 M123.3 M31.8 M
Slightly volatile
Total Liabilities21.4 M12.2 M24.9 M
Very volatile
Deferred Long Term Liabilities492.8 K554.4 K604.5 K
Slightly volatile
Property Plant And Equipment Gross3.3 M5.2 M1.8 M
Slightly volatile
Short and Long Term Debt3.1 M3.2 M4.5 M
Slightly volatile
Total Current Assets10.7 M10.2 M2.2 M
Slightly volatile
Capital Stock2.6 K2 K2.2 K
Slightly volatile
Short Term Debt3.6 M4.4 M4.9 M
Slightly volatile
Common Stock2.6 K2 K2.2 K
Slightly volatile
Property Plant Equipment877.8 K1.2 M802.3 K
Slightly volatile
Net Receivables1.6 M1.6 M286.1 K
Slightly volatile
Non Current Liabilities Other1.6 M1.8 M2 M
Slightly volatile

Calidi Biotherapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Tax Provision13.6 K14 K7.2 K
Slightly volatile
Depreciation And Amortization1.6 M1.5 M374.7 K
Slightly volatile
Interest Expense1.2 M933 K530.2 K
Slightly volatile
Selling General Administrative12 M12.9 M6.4 M
Slightly volatile
Other Operating Expenses20.2 M21.8 M11.2 M
Slightly volatile
Research Development8.1 M8.9 M4.8 M
Slightly volatile
Total Operating Expenses19.8 M21.8 M11.1 M
Slightly volatile
Reconciled Depreciation1.6 M1.5 M378.1 K
Slightly volatile
Income Tax Expense12.3 K14 K6.8 K
Slightly volatile

Calidi Biotherapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings1.3 M1.9 M1.7 M
Slightly volatile
Stock Based Compensation3.6 M3 M1.8 M
Slightly volatile
Begin Period Cash Flow1.1 M2.2 M978.2 K
Pretty Stable
Depreciation1.6 M1.5 M427.5 K
Slightly volatile
Capital Expenditures15.2 K16 K319.4 K
Slightly volatile
Change To Operating Activities1.4 M2.2 M1 M
Slightly volatile
Total Cash From Financing Activities18.3 M27.4 M9.3 M
Slightly volatile
End Period Cash Flow10.3 M9.8 M1.9 M
Slightly volatile
Change To Netincome10 M9.5 M3.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1 K1.7 K880
Slightly volatile
Dividend Yield0.140.160.1782
Slightly volatile
Days Sales Outstanding5.656.356.9246
Slightly volatile
Stock Based Compensation To Revenue12912335.0217
Slightly volatile
Capex To Depreciation0.00990.01041.4297
Slightly volatile
EV To Sales1.1 K1.8 K913
Slightly volatile
Payables Turnover0.780.74080.2429
Slightly volatile
Sales General And Administrative To Revenue33431895.2155
Slightly volatile
Research And Ddevelopement To Revenue15214546.5619
Slightly volatile
Capex To Revenue8.998.562.6299
Slightly volatile
Cash Per Share15.1614.43533.468
Slightly volatile
Days Payables Outstanding4684932.1 K
Slightly volatile
Income Quality0.490.88680.6005
Very volatile
Current Ratio1.131.0770.2086
Slightly volatile
Receivables Turnover41.3846.5550.7542
Slightly volatile
Capex Per Share0.02290.02410.7777
Slightly volatile
Revenue Per Share1.390.731.6234
Slightly volatile
Interest Debt Per Share11.3911.99416.0607
Slightly volatile
Debt To Assets0.470.49614.6021
Slightly volatile
Operating Cycle5.656.356.9246
Slightly volatile
Price Earnings To Growth Ratio0.00480.0050.0322
Slightly volatile
Days Of Payables Outstanding4684932.1 K
Slightly volatile
Quick Ratio1.131.0770.2086
Slightly volatile
Cash Ratio1.061.010.1775
Slightly volatile
Days Of Sales Outstanding5.656.356.9246
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.171.00081.0759
Very volatile
Fixed Asset Turnover0.04530.04770.5866
Slightly volatile
Debt Ratio0.470.49614.6021
Slightly volatile
Price Sales Ratio1 K1.7 K880
Slightly volatile
Asset Turnover0.01640.01560.0056
Slightly volatile

Calidi Biotherapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap26.5 M27.9 M2.4 B
Slightly volatile
Enterprise Value32.1 M33.8 M2.4 B
Slightly volatile

Calidi Fundamental Market Drivers

Calidi Upcoming Events

13th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
13th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Calidi Biotherapeutics Financial Statements

Investors use fundamental indicators, such as Calidi Biotherapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Calidi Biotherapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue-4.6 M-4.4 M
Cost Of Revenue1.5 M1.6 M
Stock Based Compensation To Revenue 122.86  129.00 
Sales General And Administrative To Revenue 318.04  333.94 
Research And Ddevelopement To Revenue 145.14  152.40 
Capex To Revenue 8.56  8.99 
Revenue Per Share 0.73  1.39 
Ebit Per Revenue(591.05)(561.50)

Currently Active Assets on Macroaxis

DDDupont De Nemours
CRDOCredo Technology Group
GOOGAlphabet Inc Class C
BACBank of America
CRMSalesforce
When determining whether Calidi Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Calidi Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Calidi Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Calidi Biotherapeutics Stock:
How To Invest In Calidi
Details
Is Calidi Stock a good investment?
Details
What is Calidi Biotherapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Calidi Biotherapeutics Correlation against competitors.
For more detail on how to invest in Calidi Stock please use our How to Invest in Calidi Biotherapeutics guide.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Calidi Biotherapeutics. If investors know Calidi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Calidi Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
0.36
Return On Assets
(1.20)
The market value of Calidi Biotherapeutics is measured differently than its book value, which is the value of Calidi that is recorded on the company's balance sheet. Investors also form their own opinion of Calidi Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Calidi Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Calidi Biotherapeutics' market value can be influenced by many factors that don't directly affect Calidi Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Calidi Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Calidi Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Calidi Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY